P. Barthelemy

Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group.

S. Culine, Y. Allory, S. Oudard, 2019, Clinical genitourinary cancer.

French AFU Cancer Committee Guidelines - Update 2022-2024: management of kidney cancer.

J. Bernhard, J. Correas, Z. Khene, 2022, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

Comparison of open and robotic-assisted partial nephrectomy approaches using multicentric data (UroCCR-47 study)

K. Bensalah, J. Bernhard, F. Bruyère, 2022, Scientific Reports.

LBA4 Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial

R. Motzer, P. Russo, S. Buti, 2022, Annals of Oncology.

1451MO In-situ immune markers predict nivolumab (N) +/-ipilimumab (I) efficacy in frontline metastatic clear cell renal cell carcinoma (mccRCC): Key ancillary analyses from the BIONIKK randomized trial

C. Tournigand, C. Sautès-Fridman, S. Oudard, 2022, Annals of Oncology.

1448O Phase II KEYNOTE-B61 study of pembrolizumab (Pembro) + lenvatinib (Lenva) as first-line treatment for non-clear cell renal cell carcinoma (nccRCC)

L. Lacombe, C. Gedye, P. Tomczak, 2022, Annals of Oncology.

1450MO Efficacy of a tailored approach with nivolumab and nivolumab/ipilimumab as immunotherapeutic boost in metastatic renal cell carcinoma: Final results of TITAN-RCC

M. Grimm, G. Baretton, N. Charnley, 2022, Annals of Oncology.